These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 34253119)

  • 1. Continuing trends in U.S. brand-name and generic drug competition.
    Grabowski H; Long G; Mortimer R; Bilginsoy M
    J Med Econ; 2021; 24(1):908-917. PubMed ID: 34253119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated trends in US brand-name and generic drug competition.
    Grabowski H; Long G; Mortimer R; Boyo A
    J Med Econ; 2016 Sep; 19(9):836-44. PubMed ID: 27064194
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent trends in brand-name and generic drug competition.
    Grabowski H; Long G; Mortimer R
    J Med Econ; 2014 Mar; 17(3):207-14. PubMed ID: 24320785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective Market Exclusivity of New Molecular Entities for Rare and Non-rare Diseases.
    Kerr KW; Glos LJ
    Pharmaceut Med; 2020 Feb; 34(1):19-29. PubMed ID: 32048213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The timing of 30-month stay expirations and generic entry: A cohort study of first generics, 2013-2020.
    Kannappan S; Darrow JJ; Kesselheim AS; Beall RF
    Clin Transl Sci; 2021 Sep; 14(5):1917-1923. PubMed ID: 33982425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Product-line extensions and pricing strategies of brand-name drugs facing patent expiration.
    Hong SH; Shepherd MD; Scoones D; Wan TT
    J Manag Care Pharm; 2005; 11(9):746-54. PubMed ID: 16300418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patent Challenges And Litigation On Inhalers For Asthma And COPD.
    Reddy S; Beall RF; Tu SS; Kesselheim AS; Feldman WB
    Health Aff (Millwood); 2023 Mar; 42(3):398-406. PubMed ID: 36877911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longer patents for increased generic competition in the US. The Waxman-Hatch Act after one decade.
    Grabowski H; Vernon J
    Pharmacoeconomics; 1996; 10 Suppl 2():110-23. PubMed ID: 10163428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of Paragraph IV decisions and generic entry before patent expiration on brand pharmaceutical firms.
    Panattoni LE
    J Health Econ; 2011 Jan; 30(1):126-45. PubMed ID: 21074873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Market Exclusivity Length for Drugs with New Generic or Biosimilar Competition, 2012-2018.
    Rome BN; Lee CC; Kesselheim AS
    Clin Pharmacol Ther; 2021 Feb; 109(2):367-371. PubMed ID: 32654122
    [TBL] [Abstract][Full Text] [Related]  

  • 11. OSTEOPOROSIS DRUGS MARKETED IN THE UNITED STATES: GENERIC COMPETITION, PRICING STRUCTURE, AND DISPERSION AMONG PAYERS.
    Balkhi B; Seoane-Vazquez E; Rodriguez-Monguio R
    Int J Technol Assess Health Care; 2016 Jan; 32(6):385-392. PubMed ID: 28065194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing Onset of Biosimilar Versus Generic Competition in the United States.
    Beall RF; Ronksley PE; Wick J; Darrow JJ; Sarpatwari A; Kesselheim AS
    Clin Pharmacol Ther; 2020 Dec; 108(6):1308-1314. PubMed ID: 32621540
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed-Dose Combination Drug Approvals, Patents and Market Exclusivities Compared to Single Active Ingredient Pharmaceuticals.
    Hao J; Rodriguez-Monguio R; Seoane-Vazquez E
    PLoS One; 2015; 10(10):e0140708. PubMed ID: 26469277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Competition on Generic Drug Prices.
    Nguyen NX; Sheingold SH; Tarazi W; Bosworth A
    Appl Health Econ Health Policy; 2022 Mar; 20(2):243-253. PubMed ID: 34904207
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Determinants of Market Exclusivity for Prescription Drugs in the United States.
    Kesselheim AS; Sinha MS; Avorn J
    JAMA Intern Med; 2017 Nov; 177(11):1658-1664. PubMed ID: 28892528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimating The Cost Of Delayed Generic Drug Entry To Medicaid.
    Dave CV; Sinha MS; Beall RF; Kesselheim AS
    Health Aff (Millwood); 2020 Jun; 39(6):1011-1017. PubMed ID: 32479219
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sharing, samples, and generics: an antitrust framework.
    Carrier MA
    Cornell Law Rev; 2017; 103(1):1-64. PubMed ID: 29236427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are drug prices subject to creative destruction? Evidence from the US, 1997-2017.
    Lichtenberg FR
    Health Econ; 2021 Aug; 30(8):1910-1932. PubMed ID: 33987916
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Generic entry, reformulations and promotion of SSRIs in the US.
    Huskamp HA; Donohue JM; Koss C; Berndt ER; Frank RG
    Pharmacoeconomics; 2008; 26(7):603-16. PubMed ID: 18563951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bib Pharma Monopoly: Why Consumers Keep Landing on "Park Place" and How the Game is Rigged.
    Levy MS
    Am Univ Law Rev; 2016; 66(1):247-303. PubMed ID: 28225582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.